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Abstract  
Natalizumab is a very effective, relatively new drug for the treatment of relapsing 
remitting multiple sclerosis. Inflammatory and neurodegenerative processes in the 
central nervous system are presumed to cause adverse effects during the course of 
this disease. To monitor the effects of natalizumab treatment on the cerebrospinal 
fluid (CSF) proteome of patients, CSF samples were taken from patients before 
commencing treatment as well as after one year of treatment. 
Profiling proteomics experiments using electrospray Orbitrap mass spectrometry and 
pair wise comparison of patients before and after treatment revealed a number of 
candidate biomarkers that were significantly differentially abundant between the 
before- and after treatment groups. Three proteins were subsequently validated using 
selected reaction monitoring (SRM) in a new, independent sample set. All three 
proteins, Ig mu chain C region and haptoglobin, both known inflammation-related 
proteins, as well as chitinase-3-like protein 1, were confirmed by SRM to be 
significantly lower abundant in CSF of multiple sclerosis patients after one year of 
natalizumab treatment. The findings for chitinase-3-like protein 1, a presumed 
biomarker for conversion of clinically isolated syndrome to clinically definite multiple 
sclerosis, was further confirmed by ELISA measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Multiple sclerosis (MScl) is a common cause of neurological disability in young 
adults. The cause of the severe neurological disability is the interruption of 
myelinated tracts in the central nervous system (CNS)1.  Most pathogenesis models 
for the disease support the existence of two connected processes that occur in 
patients with MScl; inflammation and neurodegeneration2. These processes are not 
uniformly represented across patient populations but can predominate selectively in 
individual patients, contributing to the heterogeneity of phenotypic expression of the 
disease3. The majority (approximately 85%) of MScl patients have the relapsing 
remitting (RR) MScl subtype of the disease4. RR MScl is characterized by relapses 
with increased disease activity, which occur at irregular intervals, followed by periods 
of remission. It is believed that the disease process starts with increased migration of 
auto-reactive lymphocytes across the blood-brain barrier5.  
Treatment for RR MScl is focused on the reduction of the number of relapses. These 
therapeutic agents, such as interferon beta and glatiramer acetate, are only 
moderately effective and reduce the annualized relapse rate by about a third6-7. 
The monoclonal antibody natalizumab (brand name: Tysabri) is an effective agent in 
the prevention of clinical relapses in relapsing remitting multiple sclerosis patients, 
reducing the relapse rate by 68%8. The therapeutic effect of natalizumab is thought to 
be mediated by suppression of leukocyte migration into the central nervous system 
by blocking the Very-Late Activation Antigen 4 ligand on immune cells9. As a 
consequence, a reduction of inflammation and inflammatory mediators might be 
observable in the central nervous system of natalizumab treated patients. However, 
neurodegeneration-related proteins were recently also reported to be influenced by 
natalizumab treatment10. 
In this study, we employed state-of-the-art quantitative proteomics techniques to 
differentiate between cerebrospinal fluid (CSF) samples of multiple sclerosis patients 
before and after treatment with natalizumab. 
 
 
Methods 
CSF samples were taken from relapsing remitting MScl patients before natalizumab 
treatment commenced at the University Medical Center Eppendorf (Hamburg, 
Germany). The post-treatment samples were taken at the same hospital one year 
after the start of Tysabri treatment. The Tysabri treatment consisted of a year-long 
treatment of monthly natalizumab infusion (300 mg intravenously, infused over 
approximately one hour, every four weeks). All patients gave their consent for the 
repeated CSF sampling. Immediately after sampling, the CSF samples were 
centrifuged for 10 min at 3000 rpm to discard cells and cellular elements. The 
samples were subsequently used for routine CSF diagnostics, which included 
quantification of total protein concentration (table 1). The remaining volume of the 
samples was aliquoted and stored at -80°C, where they remained until sample 
preparation for this study. The sample details are listed in table 1 (discovery sample 
set column). 
From each CSF sample, 20 μL was added to 20 μL of 0.2% Rapigest (Waters, 
Milford, MA) in 50 mM ammonium bicarbonate buffer. After 30 min incubation periods 
with 1,4-dithiothreitol (60 °C) and, subsequently, iodoacetamide (37 °C), 4 μL of 0.1 
μg/μL gold-grade trypsin (Promega, Madison, WI)/3 mM Tris-HCl (pH 8.0) was added 
to each sample. The samples were incubated overnight at 37 °C. To adjust the pH of 
the digest to pH < 2, trifluoroacetic acid (TFA) was added to the mixture prior to the 
final incubation step at 37 °C for a duration of 45 minutes to stop the enzymatic 
digestion reaction. 
Mass spectrometry measurements were carried out on a Ultimate 3000 nano LC 
system (Dionex, Germering, Germany) online coupled to a hybrid linear ion 
trap/Orbitrap MS (LTQ Orbitrap XL; Thermo Fisher Scientific, Germany). Five µL 
digest were loaded on to a C18 trap column (C18 PepMap, 300 µm ID ×5 mm, 5 µm 
particle size, 100 Å pore size; Dionex, The Netherlands) and desalted for 10 minutes 
using a flow rate of 20 µL/min 0.1% TFA. Then the trap column was switched online 
with the analytical column (PepMap C18, 75 µm ID ×150 mm, 3 µm particle and 100 
Å pore size; Dionex, The Netherlands) and peptides were eluted with following binary 
gradient: 0%–25% solvent B in 120 min and 25%–50% solvent B in further 60 
minutes, where solvent A consist of 2% acetonitrile and 0.1% formic in water and 
solvent B consists of 80% acetonitrile and 0.08% formic acid in water. Column flow 
rate was set to 300 nL/min. For MS detection a data dependent acquisition method 
was used: high resolution survey scan from 400–1800 Th. was performed in the 
Orbitrap (value of target of automatic gain control AGC 106, resolution 30,000 at 400 
m/z; lock mass was set to 445.120025 u (protonated (Si(CH3)2O)611). Based on this 
survey scan the 5 most intensive ions were consecutively isolated (AGC target set to 
104 ions) and fragmented by collision-activated dissociation (CAD) applying 35% 
normalized collision energy in the linear ion trap. After precursors were selected for 
MS/MS, they were excluded for further MS/MS spectra for 3 minutes.  
The raw data was pre-processed using the Progenesis LC-MS software package 
(version 2.6, Nonlinear Dynamics, Newcastle-upon-Tyne, United Kingdom). Peptides 
were identified and assigned to proteins by exporting features, for which MS/MS 
spectra were recorded, using the Bioworks software package (version 3.2; Thermo 
Fisher Scientific, Germany; peak picking by Extract_msn, default settings). The 
resulting .mgf file was submitted to Mascot (version 2, Matrix Science, London, 
United Kingdom) for identification to interrogate the UniProt-database (release 
2010_04; taxonomy: Homo sapiens, containing 77399 sequences). Only ions with 
charge states between +2 and +7 were considered and only proteins with at least two 
unique peptides (Mascot sore > 25) assigned to them were accepted as true 
identifications. Modifications: carbamidomethylation of cysteine was set as fixed and 
oxidation of methionine as variable modification, allowing a maximum of 2 missed 
cleavages. Mass tolerance for precursor ions was set to 10 ppm and for fragment 
ions at 0.5 Da. The Mascot search results were imported back into the Progenesis 
software to link the identified peptides to the detected abundances of these peptides. 
Subsequently the data were exported in Excel format.  
The raw abundances of all identified peptides were compared between the groups of 
samples (before and after treatment with natalizumab) by performing a paired t-test 
on all individual peptides. Proteins of which 50% or more of the peptides had a low p-
value in this t-test (p<0.01) were deemed to be significantly differentially abundant 
between the two groups. 
 
Validation by Selected Reaction Monitoring 
To validate the found differentially abundant proteins a validation sample set of CSF 
samples of natalizumab treated patients was collected at the Karolinska Institute in 
Stockholm, Sweden. The CSF samples, which were taken from 20 patients both 
before and after treatment were stored at -80°C before shipping on dry ice to the 
analysis laboratory (Table 1). Subsequently these samples were enzymatically 
digested following the exact same protocol as used for the original samples. The 
digested CSF samples were spiked with known concentrations of stable isotope-
labelled peptide standards corresponding to sequences 100-112 (NVPLPVIAELPPK) 
and 113-120 (VSVFVPPR) of Ig mu chain C region (P01871), sequences 119-131 
(TEGDGVYTLNNEK) and 162-170 (ILGGHLDAK) of haptoglobin (P00738), and 
sequences 322-335 (GNQWVGYDDQESVK) and 370-377 (FPLTNAIK) of chitinase-
3-like protein 1 (P36222) for quantification by selected reaction monitoring (SRM). 
Peptides in spiked CSF digests were separated by reversed-phase chromatography 
on an Ultimate 3000 nano LC system (Dionex). Spiked CSF digest (1 μL) was loaded 
onto a C18 trap column (PepMap C18, 300 μm ID by 5 mm length, 5 μm particle size 
and 100 Å pore size; Dionex) and washed for 5 min at a flow rate of 20 μL/min with 
0.1% TFA in H2O. Next, the trap column was switched in line with the analytical 
column (PepMap C18, 75 μm ID by 150 mm length, 3 μm particle size and 100 Å 
pore size; Dionex). Peptides were eluted at a flow rate of 300 nL/min with the 
following gradient: 0%–45% solvent B in 30 min, where solvent A is H2O/acetonitrile 
(ACN) 98%/2% (vol/vol), 0.1% formic acid (FA) and solvent B is H2O/ACN 20%/80% 
(vol/vol), 0.1% FA. Separation of the peptides was monitored with a UV detector 
(absorption at 214 nm). 
SRM analysis was performed on an ESI triple quadrupole (ESI-QqQ) tandem mass 
spectrometer (4000 QTRAP; AB Sciex, Concord, Canada) in the positive ion mode. 
Three transitions were quantified for all peptides (NVPLPVIAELPPK, transitions y3, 
y9, and y11; VSVFVPPR, transitions y3, y4 and y5; ILGGHLDAK, transitions b6, b7 
and y7; GNQWVGYDDQESVK, transitions y7, y8 and y9; and FPLTNAIK, transitions 
y5, y6 and y7). No transitions could be quantified for the TEGDGVYTLNNEK peptide 
of haptoglobin, as this peptide could not be detected on the ESI-QqQ. Hence 
haptoglobin was quantified on the values obtained for the ILGGHLDAK peptide only. 
We performed data analysis using the SRM data analysis program Skyline (version 
1.1). Concentrations of the analyte peptides were determined based on the ratio 
between the peak area of the analyte peptide to the peak area of the spiked isotope-
labelled internal peptide standard, which was added at a known concentration. 
 
Validation of Chitinase-3-like protein 1 by ELISA 
To further confirm the differential abundance of chitinase-3-like protein 1 between 
untreated and natalizumab treated multiple sclerosis patients, an ELISA for this 
protein was purchased, and performed according to the manufacturers (R&D 
Systems, Abingdon, United Kingdom) instructions. 
 
 Results 
Using ESI-Orbitrap mass spectrometry a total of 3289 peptides were identified during 
the measurements of the “before treatment” and “after treatment” CSF samples of the 
seventeen relapsing remitting multiple sclerosis patients in the discovery sample set. 
These peptides relate to 578 unique proteins, of which 301 were identified by 2 or 
more peptides. Using a paired t-test to compare the CSF samples from before 
treatment to the samples from after treatment, 122 peptides had a p-value below 0.01 
(statistical background determined by permutation: 33+/- 21). For fourteen proteins 
50% or more of the peptides had a p-value lower than 0.01, fulfilling the pre-set 
criterion for differential abundance (Table 2). Of these proteins five were identified by 
multiple peptides, namely haptoglobin, Ig mu chain C region, Ig mu heavy chain 
disease protein, serine protease inhibitor and scavenger receptor cysteine-rich type 1 
protein M130.  
Additionally, chitinase-3-like protein 1, a potential CSF marker for conversion of 
clinically isolated syndrome of demyelination (CIS) to clinically definite MScl12, was 
identified by eleven unique peptides. One of these peptides had a significant p-value 
in the statistical analysis, and an additional six peptides showed low, nearly 
significant p-values (between 0.016 and 0.071). All peptides of chitinase-3-like 
protein 1 were decreased in the Orbitrap measurements of the CSF samples after 
treatment. Hence, although not statistically significant according to the predetermined 
criteria, this protein did show a trend towards statistical significance. Because this 
protein has been previously implicated as a conversion factor for CIS to MScl, we 
decided to include chitinase-3-like protein 1 in the validation stage of the study. 
The majority of proteins related to the inflammatory response, including previously 
reported potential markers for multiple sclerosis complement C3, complement C4 and 
clusterin13, were lower abundant after natalizumab treatment, although this did not 
reach statistical significance, with the exception of haptoglobin and the 
immunoglobulin proteins listed in table 2. Previously reported markers of 
neurodegenerative processes, chromogranin A and contactin-114, were not 
significantly changed after treatment, although both proteins were higher abundant 
after treatment. None of the four proteins reported to be decreased in abundance 
after six months of natalizumab treatment by Ottervald et al.10 was statistically 
significantly changed after six months of natalizumab treatment. Alpha-1 
antichymotrypsin was slightly less abundant after treatment and the other three 
proteins, contactin-1, neuronal cell adhesion molecule and neural cell adhesion 
molecule 1, were slightly more abundant after treatment 
Three proteins, haptoglobin, Ig my chain C region and chitinase-3-like protein 1, were 
selected for validation using SRM. This validation procedure showed that the 
peptides of these proteins were significantly lower in concentration in CSF of MScl 
patients after treatment with natalizumab in a new, independent sample set (p = 
0.038 and p = 0.044 for chitinase-3-like protein 1, p = 0.024 and p = 0.025 for Ig mu 
chain C region, and p = 0.002 for haptoglobin, Figure 1), confirming the results 
obtained by the ESI-Orbitrap.  
Additionally, an ELISA for chitinase-3-like protein 1 was performed for further 
confirmation, which showed a significant decrease in abundance of this protein after 
treatment (p = 0.004) in CSF of MScl patients in the validation sample set (Figure 2). 
 
 
Discussion 
In this study, we analyzed the CSF proteome of MScl patients treated with 
natalizumab to assess the effects of the drug on the proteins in the CSF by 
comparing paired samples from patients before treatment and twelve months after 
treatment. Overall the changes in the CSF proteome after twelve months treatment 
with natalizumab were limited, but we were able to make a number of interesting 
observations. 
The observation that the proteins related to inflammation are less abundant in CSF 
after natalizumab treatment is in line with the proposed mechanism of action of the 
drug15. Natalizumab, a humanized monoclonal IgG4κ antibody, selectively binds to 
the α4-integrin component of adhesion molecules found on lymphocytes and 
monocytes. This binding inhibits interaction with cells expressing the ligand of VLA-4, 
vascular cell adhesion molecule-1 (VCAM-1), consequently blocking adherence of 
activated leukocytes to endothelial cells, which is a required step of the extravasation 
into inflamed tissue16. Hence inflammation is inhibited in MScl patients due to the fact 
that natalizumab prevents the migration of autoreactive leukocytes out of blood 
vessels into target organs, such as the CNS, by blocking the adhesion molecules of 
the α4-integrin component of adhesion molecules on leukocytes.  
Also in line with the proposed mechanism of natalizumab is the lack of significantly 
differentially abundant neurodegenerative proteins after treatment. As the drug 
mechanism firmly points towards an effect on the inflammatory part of the disease 
processes, an effect on neurodegeneration was not directly expected to be observed 
here. Although a previous study shows that axonal damage in MScl is reduced by 
natalizumab treatment, it is anticipated that a highly effective anti-inflammatory 
treatment reduces axonal loss, as inflammatory activity is associated with axonal 
damage17. Consequently, these neurodegenerative effects are likely secondary to 
inflammatory processes. In contrast to the study by Ottervald and co-workers, in the 
presented study CSF samples from 6 months after the start of natalizumab treatment 
were not included10. The neurodegeneration-related proteins, alpha-1 
antichymotrypsin, contactin-1, neuronal cell adhesion molecule and neural cell 
adhesion molecule 1, which Ottervald et al. described as significantly less abundant 
after six months of treatment, but not after twelve months treatment, were not 
significantly differentially abundant after twelve months of natalizumab treatment in 
our study. Since no CSF samples were taken after six months of natalizumab 
treatment and analysed in this study, as well as the fact that the experimental 
procedures differed substantially between the studies, it is difficult to compare them. 
Three of the four proteins were even slightly higher abundant after treatment, 
although these values did not reach significant levels. Hence, no proteins that had 
previously been related to neurodegenerative effects in MScl could be observed in 
CSF to be affected by natalizumab treatment in this study. 
The majority of differentially abundant proteins found to be less abundant after 
natalizumab treatment (Table 2) is related to the inflammatory response, which is in 
the pathogenetic hallmark of MScl. Consequently, the observation that inflammatory 
response-related proteins with a known higher abundance in CSF of MScl patients 
such as immunoglobulins and haptoglobin18 are downregulated after treatment with a 
drug that blocks the entry of inflammatory cells into the CNS and the subsequent 
inflammatory effects stands to reason. All proteins identified as significantly higher 
abundant after treatment were only identified by a single peptide, which is less 
reliable than identification by multiple peptides. Two of the differentially abundant 
proteins, haptoglobin and Ig mu chain C region (both lower abundant after 
treatment), were subsequently validated by a different, quantitative mass 
spectrometry method in an independent data set. The validation experiment 
confirmed the Orbitrap profiling results for both proteins even though one of the 
peptides of haptoglobin could not be quantified for technical reasons. 
The third and final protein that was quantified in the SRM validation experiment, 
chitinase 3-like protein 1, was not significantly differentially abundant according to the 
stringent criteria set for the Orbitrap profiling experiments (p < 0.01 for 50% of the 
peptides of a protein). However the fact that a clear trend towards statistical 
significance could be observed, coupled with a report that chitinase 3-like protein 1 is 
a potential marker for conversion of CIS to clinically definite MScl12, prompted the 
inclusion of this protein in the validation experiment. Both the validation by SRM (2 
peptides, p = 0.038 and p = 0.044) as well as by ELISA (p = 0.004) confirmed the 
Orbitrap profiling experiment. The difference p-values between the validation 
(statistically significant) and profiling (not statistically significant) experiments is most 
likely due to the selectivity of the validation method, as accurate quantification is 
more reliable using targeted methods such as SRM and ELISA, compared to 
untargeted methods like full scan label free Orbitrap measurements. 
Chitinase 3-like protein 1, which is also known as YKL40, is a chitin-binding, but 
chitinase activity-lacking member of the glycoside hydrolase 18 chitinase family19. 
One of the main cell types that secretes this protein are macrophages, linking the 
protein to the inflammatory response. Increased abundance of this protein in all 
likelihood is not specific for conversion of CIS to MScl or response to natalizumab 
treatment in MScl patients, but rather a marker for inflammatory activity in the 
affected compartment, which is supported by the observation of increased levels in 
serum of several types of cancers and diseases such as rheumatoid arthritis20-22. 
Additionally, the role of the chitinase family in the pathogenesis of MScl is further 
exemplified by the observation of increased plasma levels of chitotriodase in MScl 
patients compared to controls23-24. 
In conclusion, natalizumab treatment of MScl patients results in a decrease in the 
levels of inflammation-related proteins in the CSF, which is in line with the proposed 
mechanism of action of natalizumab. CSF proteins related to neurodegeneration 
were not affected by natalizumab treatment. A decrease in the CSF levels of 
chitinase 3-like protein 1, a potential marker for conversion of CIS to clinically definite 
MScl, was also observed in the patients after twelve months treatment with 
natalizumab. 
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Table 1: Details of all patients and related samples included in this study (discovery and validation sample sets). The values for 
age, disease duration, EDSS score (Expanded Disability Status Scale) and protein concentrations are averages (with standard 
deviation in brackets). In both sample sets the change in EDSS , as well as the protein concentration in the discovery sample set, 
from before treatment to after treatment is not significant (p>0.01). 
 
 Discovery set samples (Germany) Validation set samples (Sweden) 
Gender distribution (M/F) 4/13 5/15 
Age (years) 37.1 (8.1) 41.4 (9.8) 
Disease duration (years) 8.4 (5.8) 11.2 (6.6) 
EDSS before treatment 3.7 (1.3) 4.3 (1.9) 
EDSS after treatment 3.6 (1.4) 4.2 (1.9) 
Protein concentration before treatment 
(mg/L) 
381.7 (75.1) - 
Protein concentration after treatment 
(mg/L) 
318.8 (87.3) - 
 
 
 
 
 
 
 
Table 2:  The fourteen peptides identified as differentially abundant between the “before treatment” and “after treatment” groups. 
Primary 
accession 
number 
Protein Number of peptides 
with p<0.01 / total 
number of peptides 
Higher abundant 
in group 
P00738 Haptoglobin 15/26 Before treatment 
P01591 Immunoglobulin J chain 1/1 Before treatment 
P01606 Ig kappa chain V-I region OU 1/1 Before treatment 
P01871 Ig mu chain C region 7/12 Before treatment 
P04220 Ig mu heavy chain disease protein 1/2 Before treatment 
P05154 Serine protease inhibitor 1/2 Before treatment 
P08133 Annexin A6 1/1 Before treatment 
Q86VB7 Scavenger receptor cysteine-rich type 1 protein M130 1/2 Before treatment 
P07108 Acyl-CoA-binding protein 1/1 After treatment 
P32004 Neural cell adhesion molecule L1 1/1 After treatment 
Q5FWE3 Proline-rich transmembrane protein 3 1/1 After treatment 
Q8IZJ4 Ral-GDS-related protein 1/1 After treatment 
Q8WXK8 Bullous pemphigoid antigen 1, isoform 7 (fragment) 1/1 After treatment 
Q9BQT9 Calsyntenin-3 1/1 After treatment 
 
 
 
Figure legends 
 
Figure 1 
SRM results for the three proteins selected for validation. Panels A and B show two peptides of chitinase 3-like protein 1 to be 
significantly lower abundant in CSF after natalizumab treatment (p = 0.038 and p = 0.044). Panels C and D show the same for two 
peptides of Ig mu chain C region (p = 0.024 and p = 0.025). Panel E shows the ILGGHLDAK peptide of haptoglobin to be 
significantly lower abundant after treatment (p = 0.002). All p-values were obtained using a paired t-test as these samples are 
paired CSF samples from the same patients before and after treatment. 
 
 
Figure 2 
Concentrations of chitinase 3-like protein 1 in CSF of MScl patients before (red) and after (blue) treatment with natalizumab as 
determined by ELISA. The concentration of this protein in CSF is significantly lower after treatment (p = 0.004). 
 
 
 
 
 
 
 
